Loading clinical trials...
Loading clinical trials...
A Phase II, Multicentre, Open Label Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia
Conditions
Interventions
CPX-351
Locations
12
Spain
Institut Català D'Oncologia-Hospital Germans Trias I Pujol
Badalona, Spain
Institut Català D'Oncologia - Hospital Duran I Reynals
Bellvitge, Spain
Hospital San Pedro de Alcántara
Cáceres, Spain
Hospital Universitario Reina Sofía
Córdoba, Spain
Hospital Universitario de Gran Canaria Dr. Negrín
Las Palmas, Spain
Hospital Universitario Lucus Augusti
Lugo, Spain
Start Date
December 26, 2019
Primary Completion Date
April 30, 2021
Completion Date
August 11, 2021
Last Updated
September 8, 2022
Lead Sponsor
PETHEMA Foundation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions